Overview

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Status:
Completed

Trial end date:
2020-08-04

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cisplatin
Pembrolizumab